pwc glp 1 GLP-1 Adoption Drives Consumer Behavior Shifts | US Consumer Markets posted on the topic Oral GLP-1: how to win

The company is moving forward with larger clinical trials to further evaluate amycretins potential and clarify its place in an increasingly competitive field

N.VanderBeekB

Step 2: Consult with a Licensed Provider

Cardiovascular outcome trials show that treatment with long-acting GLP-1 medicines such as liraglutide, dulaglutide, and semaglutide reduces cardiovascular events in people living with T2D and with semaglutide also in people living with obesity (6062)

We sat down with him to discuss the strides GLP-1s have made over the last couple years and where research is headed

The share who report ever taking these drugs rises to about four in ten (43%) among adults who have been told by a doctor that they have diabetes, a quarter (26%) of adults who have been told they have heart disease, and one in five (22%) adults who have been told by a doctor that they are overweight or obese in the past five years (some of whom also have diabetes or heart disease)